Teligent Inc (NASDAQ: TLGT), a specialty generic pharmaceutical firm, revealed Monday that it got the FDA approval for its abbreviated new drug application (ANDA) of Triamcinolone Acetonide Ointment ...
Teligent announced that the Food and Drug Administration (FDA) has approved Triamcinolone Acetonide Ointment, 0.1%. Triamcinolone Acetonide Ointment is a topical steroid indicated for the relief of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved triamcinolone acetonide ointment for the treatment of inflammatory and pruritic ...
Glenmark’s current portfolio consists of 116 products authorised for distribution in the US marketplace Glenmark has been granted final approval by the US FDA for triamcinolone acetonide ointment USP, ...
Alembic Pharmaceuticals Limited confirmed that its joint venture Aleor Dermaceuticals Limited has gained the final FDA clearance for its Abbreviated New Drug Application (ANDA) for Nystatin and ...
Alembic Pharmaceuticals Alembic today announced that its joint venture Aleor Dermaceuticals Aleor has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug ...
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its ...
Alembic's joint venture, Aleor Dermaceuticals has received the Food and Drug Administration’s clearance for generic Nystatin and Triamcinolone Acetonide ointment. The medication is used for the ...
NEW DELHI: Glenmark Pharmaceuticals has received final approval from the US health regulator USFDA for triamcinolone acetonide ointment, used in treatment of various skin conditions. "Glenmark ...
Share price of Glenmark Pharma gained nearly 2 percent intraday Wednesday on USFDA approval. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results